Spot gold softer in thin trade as oil rebound, U.S.-Iran uncertainty cloud rate outlook
Spot gold prices are lower and spot silver prices are also weaker in early U.S. trading Monday, pres…

VITAS average daily census (ADC) growth and admission trends - organic growth typically 2-4% annually driven by aging demographics and market share gains from smaller hospice providers
Medicare reimbursement rate updates - annual market basket increases (typically 2-3%) directly impact 80% of revenue, with potential policy changes to hospice payment reform
VITAS length-of-stay and acuity mix - longer stays improve profitability but very long stays (180+ days) trigger Medicare cap exposure; routine home care mix optimization drives margin
Roto-Rooter same-store sales growth and commercial demand - residential demand relatively stable, commercial segment more cyclical and tied to construction activity and business investment
low - VITAS hospice services are non-discretionary end-of-life care with 90% Medicare funding, making revenue largely recession-resistant and driven by demographic trends rather than economic cycles. Roto-Rooter's residential emergency services (60-65% of segment revenue) are also non-discretionary, though commercial plumbing and elective residential projects show moderate sensitivity to business investment and consumer confidence. Overall company revenue demonstrates <5% correlation to GDP fluctuations.
Rising rates have minimal direct impact given low leverage (0.13 debt/equity) and modest borrowing needs. However, higher rates can pressure valuation multiples for stable cash flow businesses, as investors compare yields to fixed income alternatives. VITAS expansion through tuck-in acquisitions (typical 6-8x EBITDA multiples for small hospice providers) becomes more expensive in higher rate environments. Roto-Rooter franchise expansion and housing turnover (which drives plumbing upgrades) show modest negative correlation to mortgage rates.
Medicare hospice payment reform risk - CMS has proposed changes to the two-tier payment system and potential caps on routine home care lengths-of-stay, which could compress margins if very long-stay patients (currently ~8-10% of census) face reimbursement reductions
Hospice industry consolidation and competitive intensity - private equity-backed roll-ups and national chains (Encompass Health, Amedisys) increasing competition for referrals from hospitals and physicians, potentially pressuring admission growth and requiring higher sales/marketing spend
Labor availability and wage inflation in healthcare - nursing and home health aide shortages in tight labor markets increase costs and limit census growth capacity, with wage pressures typically exceeding Medicare reimbursement rate increases by 100-200 basis points
value/dividend - Attracts investors seeking defensive healthcare exposure with 1.0% dividend yield, consistent free cash flow generation (5.4% FCF yield), and modest growth (7-8% revenue CAGR). The combination of non-cyclical hospice revenue (80% of business) and essential services (Roto-Rooter) appeals to quality-focused value investors prioritizing capital returns and downside protection. Limited growth optionality versus high-growth healthcare peers, but superior cash generation and 24% ROE compensate through buybacks (company has reduced share count ~2% annually).
Trend
+2.6% vs SMA 50 · -2.9% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $2.3B $2.3B–$2.3B | — | $19.93 | — | ±0% | Low1 |
FY2024 | $2.4B $2.4B–$2.4B | ▲ +3.9% | $23.08 | ▲ +15.8% | ±0% | Low2 |
FY2025 | $2.5B $2.5B–$2.6B | ▲ +5.0% | $22.15 | ▼ -4.0% | ±1% | Moderate3 |
Dividend per payment — last 8 periods
Spot gold prices are lower and spot silver prices are also weaker in early U.S. trading Monday, pres…

chemed is a holding company. our wholly owned subsidiaries are vitas and roto-rooter services company. vitas is a healthcare company that specializes in hospice or end of life care for the terminally ill. roto-rooter is the nation's largest provider of plumbing and drain care services.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CHE◀ | $422.73 | -0.66% | $5.6B | 22.2 | +405.9% | 1048.4% | 1500 |
| $404.56 | +0.00% | $2.1T | — | — | — | 1500 | |
| $91.43 | +0.00% | $316.0B | 14.1 | — | 1510.7% | 1500 | |
| $134.76 | +0.00% | $305.1B | 23.7 | — | 1305.9% | 1500 | |
| $184.37 | +0.00% | $286.4B | 27.2 | +862.9% | 1745.9% | 1500 | |
| $145.51 | +0.00% | $279.7B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $89.10 | +0.00% | $251.9B | 14.4 | — | 668.4% | 1500 | |
| Sector avg | — | -0.09% | — | 20.4 | +622.0% | 1473.9% | 1500 |